The updated guidelines incorporate broader indications for therapy, including a lower cut-off for the APRI score (0.5 instead of 2.0), an ALT level above the upper limit of normal instead of two times the upper limit of normal, and comorbidities such as diabetes mellitus. This evidence concerns the gene GPT and diabetes mellitus.